{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:44:48Z","timestamp":1793270688382,"version":"4.5.0"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ZonMw (NL)","award":["836011009"],"award-info":[{"award-number":["836011009"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0182379","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T13:33:47Z","timestamp":1501594427000},"page":"e0182379","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":102,"title":["Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3016-1572","authenticated-orcid":true,"given":"Maarten","family":"Arends","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Biegstraaten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Oder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver T.","family":"Watkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric M.","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 B. P.","family":"van Kuilenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E. M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,8,1]]},"reference":[{"issue":"3922","key":"ref1","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.167.3922.1268","article-title":"Fabry's disease: alpha-galactosidase deficiency","volume":"167","author":"JA Kint","year":"1970","journal-title":"Science"},{"issue":"21","key":"ref2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"RO Brady","year":"1967","journal-title":"The New England journal of medicine"},{"key":"ref3","article-title":"OMMBID\u2014The Online Metabolic and Molecular Bases of Inherited Diseases","author":"RJ Desnick","year":"2013"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"KD MacDermot","year":"2001","journal-title":"Journal of medical genetics"},{"key":"ref5","article-title":"Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study","author":"M Arends","year":"2017","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/8904_2014_342","article-title":"Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up","volume":"17","author":"L van der Tol","year":"2014","journal-title":"JIMD reports"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2014.09.001","article-title":"Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance","volume":"177","author":"BE Smid","year":"2014","journal-title":"International journal of cardiology"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"KD MacDermot","year":"2001","journal-title":"Journal of medical genetics"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"MJ van Breemen","year":"2011","journal-title":"Biochimica et biophysica acta"},{"issue":"21","key":"ref10","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"R Schiffmann","year":"2001","journal-title":"Jama"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry's disease","volume":"345","author":"CM Eng","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain","volume":"8","author":"SM Rombach","year":"2013","journal-title":"Orphanet journal of rare diseases"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"F Weidemann","year":"2013","journal-title":"Journal of internal medicine"},{"key":"ref14","article-title":"Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease","author":"M Lenders","year":"2016","journal-title":"Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association\u2014European Renal Association"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"M Banikazemi","year":"2007","journal-title":"Annals of internal medicine"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"e0124987","DOI":"10.1371\/journal.pone.0124987","article-title":"Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial","volume":"10","author":"FA Wijburg","year":"2015","journal-title":"PloS one"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/HCO.0000000000000308","article-title":"Fabry disease: will markers of early disease enable early treatment and better outcomes?","volume":"31","author":"DA Hughes","year":"2016","journal-title":"Curr Opin Cardiol"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"M Biegstraaten","year":"2015","journal-title":"Orphanet journal of rare diseases"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ymgme.2015.11.014","article-title":"Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohort","volume":"117","author":"M Arends","year":"2016","journal-title":"Molecular genetics and metabolism"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-6-16","article-title":"Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders","volume":"6","author":"CE Hollak","year":"2011","journal-title":"Orphanet journal of rare diseases"},{"key":"ref21","unstructured":"ZonMW. Treatment of patients with Fabry disease with agalsidase alfa and agalsidase beta: phenotypic diversity necessitates the development of individualized treatment guidelines. 2013 [cited 2017 2017-01-15]. https:\/\/www.zonmw.nl\/nl\/onderzoek-resultaten\/doelmatigheidsonderzoek\/programmas\/project-detail\/goed-gebruik-geneesmiddelen\/treatment-of-patients-with-fabry-disease-with-agalsidase-alfa-and-agalsidase-beta-phenotypic-divers\/<\/ext-link>."},{"key":"ref22","first-page":"1","article-title":"KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"3","year":"2013","journal-title":"Kidney International Supplements"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology","volume":"18","author":"RM Lang","year":"2005","journal-title":"Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00004728-200605000-00013","article-title":"Left ventricular papillary muscle mass: relationship to left ventricular mass and volumes by magnetic resonance imaging","volume":"30","author":"J Vogel-Claussen","year":"2006","journal-title":"J Comput Assist Tomogr"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12471-016-0805-y","article-title":"Impact of the papillary muscles on cardiac magnetic resonance image analysis of important left ventricular parameters in hypertrophic cardiomyopathy","volume":"24","author":"DH Gommans","year":"2016","journal-title":"Neth Heart J"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12968-015-0111-7","article-title":"Normal values for cardiovascular magnetic resonance in adults and children","volume":"17","author":"N Kawel-Boehm","year":"2015","journal-title":"Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic Resonance"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","article-title":"Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry","volume":"59","author":"H Gold","year":"2013","journal-title":"Clin Chem"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jchromb.2011.11.020","article-title":"Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry","volume":"883\u2013884","author":"R Kruger","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"8","key":"ref29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"E von Elm","year":"2007","journal-title":"Annals of internal medicine"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry Disease Initiative","volume":"111","author":"SM Sirrs","year":"2014","journal-title":"Molecular genetics and metabolism"},{"issue":"5","key":"ref31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"DP Germain","year":"2015","journal-title":"Journal of medical genetics"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"DG Warnock","year":"2012","journal-title":"Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association\u2014European Renal Association"},{"issue":"12","key":"ref33","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry","volume":"5","author":"C Wanner","year":"2010","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","article-title":"Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy","volume":"52","author":"DG Warnock","year":"2015","journal-title":"Journal of medical genetics"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"DP Germain","year":"2007","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","article-title":"Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment","volume":"10","author":"C Kampmann","year":"2015","journal-title":"Orphanet journal of rare diseases"},{"issue":"4","key":"ref37","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"F Weidemann","year":"2009","journal-title":"Circulation"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"e0140627","DOI":"10.1371\/journal.pone.0140627","article-title":"Left Ventricular Geometry and Blood Pressure as Predictors of Adverse Progression of Fabry Cardiomyopathy","volume":"10","author":"J Kramer","year":"2015","journal-title":"PloS one"},{"issue":"6","key":"ref39","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2014.06.019","article-title":"Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease","volume":"114","author":"J Kramer","year":"2014","journal-title":"The American journal of cardiology"},{"issue":"12","key":"ref40","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease","volume":"26","author":"F Weidemann","year":"2005","journal-title":"European heart journal"},{"issue":"11","key":"ref41","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/jnnp.2008.143693","article-title":"Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study","volume":"79","author":"S Buechner","year":"2008","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"issue":"3B","key":"ref42","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1590\/S0004-282X2006000500002","article-title":"White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up","volume":"64","author":"LB Jardim","year":"2006","journal-title":"Arq Neuropsiquiatr"},{"issue":"6","key":"ref43","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000369293","article-title":"Enzyme Replacement Therapy Stabilized White Matter Lesion Progression in Fabry Disease","volume":"38","author":"A Fellgiebel","year":"2014","journal-title":"Cerebrovascular diseases"},{"issue":"8","key":"ref44","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"JM Aerts","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"ref45","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.2004.054015","article-title":"Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A","volume":"92","author":"PM Elliott","year":"2006","journal-title":"Heart"},{"issue":"6","key":"ref46","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1023\/B:BOLI.0000045841.27968.06","article-title":"Raised HDL cholesterol in Fabry disease: response to enzyme replacement therapy","volume":"27","author":"DJ Cartwright","year":"2004","journal-title":"Journal of inherited metabolic disease"},{"issue":"2","key":"ref47","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","article-title":"Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference","volume":"91","author":"R Schiffmann","year":"2017","journal-title":"Kidney international"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0182379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:07:59Z","timestamp":1540339679000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0182379"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Shimosawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0182379","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,1]]}}}